In observance of Breast Cancer Awareness Month -2026 , ZAS Pharma Ltd.’s International Business Department (IBD) organized a day-long seminar to explore the breast cancer landscape across Latin America, Africa, CIS, and Asia.
The seminar focused on regional market insights, current anticancer therapies, upcoming portfolio opportunities, and the potential to expand access to advanced breast cancer treatments through global partnerships and pharmaceutical exports.
ZAS Pharma’s oncology portfolio includes Ribociclib, Abemaciclib, Palbociclib, Trastuzumab, Trastuzumab Deruxtecan, Olaparib, and Vinorelbine Soft Capsules, reflecting the company’s commitment to advancing access to specialty cancer medicines.
Together, we stand for greater awareness, stronger partnerships, and broader access to breast cancer care worldwide.
